prevalence rates among immigrants compared with native Europeans.
In the October 2017 issue of the Polish Archives of Internal Medicine (Pol Arch Intern Med), Kanecki et al 7 reported the first study from Poland on the incidence and prevalence of BS. This is actually the first prevalence study of BS from Eastern Europe, to the best of our knowledge. The authors report an incidence rate of 0.5 per 1 000 000 per year (95% CI, 0.35-0.61) and a point prevalence of 0.34 per 100 000, which is the second lowest prevalence rate reported from Europe after Scotland.
8 The low immigration rate from countries with high prevalence of BS to Poland may be a contributing factor to this low prevalence, but it is still lower than that in native European populations reported in studies which give separate prevalence rates for natives and immigrants in that country. 4 - 6 A recent meta -analysis emphasized that caution is needed when interpreting and comparing the results of prevalence studies for BS. 2 The authors estimated a 22 -fold higher pooled prevalence for sample surveys (also called field or population surveys), compared with census surveys. This may be explained by the fact that BS has a variable disease course. This is especially true for the severity and frequency of the symptoms. Moreover, some symptoms such as oral apthous and papulopustular lesions are not rare in the general population, and all manifestations tend to ameliorate with aging.
9 Thus, mild cases and especially those without major organ involvement may be underrepresented in census surveys. This may be even more pronounced in surveys based on hospitalization records. In the current study, which is also based on hospitalizations, the authors explain that systemic vasculitides with multiorgan involvement such as BS are usually hospitalized since treatment, and advanced diagnostic procedures that can be done in inpatient settings may be required. However, this may still be a source of bias for underreporting.
Prevalence studies are important for identifying the disease burden and planning health care needs for a condition, for determining the changes in disease prevalence in a country or a certain population over time, and for making comparisons across different populations, which helps estimate how the results of a study in a certain country may be applicable to other countries indicating the generalizability of the results. Moreover, such epidemiology studies may provide clues for pathogenesis by pointing to the role of certain genetic or environmental factors. The key issue in conducting good prevalence studies is the choice of the right sample, right methodology, and right analysis.
1 Several prevalence studies have been conducted for Behçet syndrome (BS) in different parts of the world, with different approaches regarding each of these points. Differences such as community -based versus hospital--based studies, differences in the criteria used for defining patients with BS, such as the International Study Group (ISG) criteria or the International Criteria for Behçet's Disease (ICBD) criteria, and the use of prevalence rates or prevalence odds ratios may render the interpretation and comparison of these studies difficult.
2
BS is more prevalent along the ancient Silk Route where the prevalence of HLA -B51 is high. The highest prevalence is in Turkey (420 per 100 000), followed by Iran (80 per 100 000), Iraq (17 per 100 000), Japan (7-13.5 per 100 000), and China (2.6 per 100 000). The estimated prevalence of BS varies across European countries, ranging between 0.3 and 27 per 100 000 and is higher in the southern parts.
3 It was thought that immigration may be a cause of increased BS prevalence in European countries. In a study from Germany that elaborates on this issue, the prevalence of BS was 1.47 per 100 000 among Germans and 77 per 100 000 among Turks living in Germany. 4 Similarly, 2 other studies from Sweden (13.6 vs 2.0 per 100 000)
5 and France (6.2-36.4 vs 2 per 100 000) 6 found higher
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